# Table S4. Cardiac assessments (grey shading denotes subjects with cardiac involvement)

| **Patient number** | **Amyloid type** | **Cardiac involvement** | **Parameter** | **1st value****post diagnosis** | **Value at baseline\*** | **Value at 1st follow-up** | **Value at 2nd follow-up** | **Value at 3rd follow-up** | **Value at 4th follow-up** | **Value at 5th follow-up** | **Value at 6th follow-up** | **Value at 7th follow-up** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sustained responders |
| 012 | AA | No | LV septum (mm) | 11 | 9 | 11 | 11 | – | – | – | – | – |
| LV posterior wall thickness (mm) | 11 | 9 | 10 | 10 | – | – | – | – | – |
| E:E’ | 7 | 9 | 10 | 8.4 | – | – | – | – | – |
| LVEF (%) | 75 | 65 | 70 | 70 | – | – | – | – | – |
| 107  | AL | No | LV septum (mm) | 10.7 | 9 | 8 | 9 | 10 | – | – | – | – |
| LV posterior wall thickness (mm) | 10.5 | 9 | 8 | 10 | 10 | – | – | – | – |
| E:E’ | – | 8 | 11.9 | 8 | 16 | – | – | – | – |
| LVEF (%) | – | 60 | 60 | 57 | 55 | – | – | – | – |
| 108  | AL | No | LV septum (mm) | 8 | 9 | 8 | 8 | 8 | 10 | – | – | – |
| LV posterior wall thickness (mm) | 9 | 9 | 9 | 8 | 8 | 10 | – | – | – |
| E:E’ | 6.8 | 6 | 6 | 7 | 5.481 | 6 | – | – | – |
| LVEF (%) | 61 | 58 | 66 | 60 | 60 | 60 | – | – | – |
| 110†  | AL | No | LV septum (mm) | 12 | 10 | 11 | 12 | 12 | – | – | – | – |
| LV posterior wall thickness (mm) | 11 | 11 | 11 | 8 | 12 | – | – | – | – |
| E:E’ | 6 | 6 | 6 | 6 | 9 | – | – | – | – |
| LVEF (%) | 58 | 67 | 60 | 60 | 60 | – | – | – | – |
| 113†  | AL | No | LV septum (mm) | 10 | 10 | 11 | – | – | – | – | – | – |
| LV posterior wall thickness (mm) | 11 | 10 | 10 | – | – | – | – | – | – |
| E:E’ | – | 12 | 10 | – | – | – | – | – | – |
| LVEF (%) | 57 | 60 | 60 | – | – | – | – | – | – |
| 116  | AL | No | LV septum (mm) | 9 | 10 | 8 | 9 | 9 | 10 | – | – | – |
| LV posterior wall thickness (mm) | 9 | 10 | 10 | 8 | 9 | 10 | – | – | – |
| E:E’ | 3.9 | 6 | 9.5 | 4.9 | 7.874 | 4.9 | – | – | – |
| LVEF (%) | 64 | 63 | 60 | 60 | 60 | 65 | – | – | – |
| 121  | AL | Yes | LV septum (mm) | 18 | 17 | 17 | 14 | – | – | – | – | – |
| LV posterior wall thickness (mm) | 18 | 18 | 17 | 14 | – | – | – | – | – |
| E:E’ | 17 | 18 | 31 | 17 | – | – | – | – | – |
| LVEF (%) | 59 | 53 | 48 | 45 | – | – | – | – | – |
| Declining responder |
| 102 | AFib | No | LV septum (mm) | 11 | 11 | 10 | 11 | 11 | – | – | – | – |
| LV posterior wall thickness (mm) | 11 | 10 | 10 | 10 | 11 | – | – | – | – |
| E:E’ | 7.5 | 11 | 10 | 7.6 | 13 | – | – | – | – |
| LVEF (%) | 67 | 60 | 59 | 65 | 55 | – | – | – | – |
| 104 | AFib | No | LV septum (mm) | 16 | 11 | 11 | 11 | – | – | – | – | – |
| LV posterior wall thickness (mm) | 11 | 10 | 11 | 11 | – | – | – | – | – |
| E:E’ | 6.3 | 5 | – | 6 | – | – | – | – | – |
| LVEF (%) | 63 | 60 | 60 | 60 | – | – | – | – | – |
| 105 | AFib | No | LV septum (mm) | 10 | 12 | 10 | – | – | – | – | – | – |
| LV posterior wall thickness (mm) | 11 | 10 | 10 | – | – | – | – | – | – |
| E:E’ | 7 | – | 10 | – | – | – | – | – | – |
| LVEF (%) | 60 | 60 | 60 | – | – | – | – | – | – |
| 106 | AFib | No | LV septum (mm) | 10 | 11 | 9 | 11 | – | – | – | – | – |
| LV posterior wall thickness (mm) | 11 | 10 | 10 | 11 | – | – | – | – | – |
| E:E’ | – | 7.6 | 10 | 13 | – | – | – | – | – |
| LVEF (%) | 57 | 52 | 57 | 55 | – | – | – | – | – |
| 109  | ApoAI | No | LV septum (mm) | 11 | 10 | 10 | 10 | 10 | 8 | 11 | – | – |
| LV posterior wall thickness (mm) | 11 | 10 | 10 | 10 | 9 | 9 | 9 | – | – |
| E:E’ | 6 | 7 | 6 | 7.6 | 7 | 5.3 | 8 | – | – |
| LVEF (%) | 77 | 63 | 68 | 60 | 66 | 63 | 55 | – | – |
| 111†  | AL | No | LV septum (mm) | 9 | 10 | 8 | 10 | – | – | – | – | – |
| LV posterior wall thickness (mm) | 10 | 10 | 8 | 10 | – | – | – | – | – |
| E:E’ | – | 11 | 10 | 11 | – | – | – | – | – |
| LVEF (%) | 70 | 69 | 55 | 65 | – | – | – | – | – |
| 114†  | AL | No | LV septum (mm) | 9 | 10 | 10 | 13 | 11 | 11 | – | – | – |
| LV posterior wall thickness (mm) | 9 | 9 | 9 | 13 | 10 | 10 | – | – | – |
| E:E’ | 5.4 | 6 | 4 | 4.9 | 6 | 6.745 | – | – | – |
| LVEF (%) | 74 | 63 | 60 | 64 | 66 | 60 | – | – | – |
| 115  | AL | No | LV septum (mm) | 12 | 12 | 12 | 12 | – | – | – | – | – |
| LV posterior wall thickness (mm) | 13 | 13 | 12 | 12 | – | – | – | – | – |
| E:E’ | 13 | 8 | 16 | 9.3 | – | – | – | – | – |
| LVEF (%) | 68 | 55 | 67 | 64 | – | – | – | – | – |
| 117 | AFib | No | LV septum (mm) | 12‡ | 12‡ | 12 | 13 | – | – | – | – | – |
| LV posterior wall thickness (mm) | 10‡ | 10‡ | 10 | 12 | – | – | – | – | – |
| E:E’ | 5.4‡ | 5.4‡ | 5 | 8.4 | – | – | – | – | – |
| LVEF (%) | 55‡ | 55‡ | 60 | 68 | – | – | – | – | – |
| 118  | AL | Yes | LV septum (mm) | 17 | 15 | 16 | 16 | 17 | 17 | 16 | 17 | – |
| LV posterior wall thickness (mm) | 16 | 15 | 16 | 17 | 17 | 16 | 16 | 17 | – |
| E:E’ | 22 | 24 | 20 | 20 | 20 | 16 | 22 | 18 | – |
| LVEF (%) | 45 | 52 | 50 | 62 | 50 | 49 | 50 | 38 | – |
| Non-responders |
| 119  | AL | No | LV septum (mm) | 11 | 12 | 12 | 10 | – | – | – | – | – |
| LV posterior wall thickness (mm) | 10 | 11 | 11 | 10 | – | – | – | – | – |
| E:E’ | 9.3 | 13 | 5 | 5 | – | – | – | – | – |
| LVEF (%) | 67 | 55 | 59 | 66 | – | – | – | – | – |
| 120  | AL | Yes | LV septum (mm) | 15 | 14 | 15 | – | – | – | – | – | – |
| LV posterior wall thickness (mm) | 15 | 14 | 15 | – | – | – | – | – | – |
| E:E’ | 15 | 20 | 26.9 | – | – | – | – | – | – |
| LVEF (%) | 57 | 61 | 60 | – | – | – | – | – | – |
| 123  | ATTR | Yes | LV septum (mm) | 17 | 16 | 16 | 16 | 17 | 18 | 17 | 17 | – |
| LV posterior wall thickness (mm) | 16 | 17 | 17 | 17 | 17 | 17 | 18 | 18 | – |
| E:E’ | 22 | 20 | 25 | 19 | 15 | 21 | 21 | 21 | – |
| LVEF (%) | 45 | 39 | 39 | 41 | 48 | 34 | 35 | 53 | – |
| 124  | ATTR | Yes | LV septum (mm) | 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | – |
| LV posterior wall thickness (mm) | 16 | 16 | 17 | 17 | 18 | 17 | 17 | 17 | – |
| E:E’ | 11 | 13 | 14 | 11 | 16.8 | 9.3 | 13.3 | 11.9 | – |
| LVEF (%) | 47 | 48 | 60 | 50 | 39 | 46 | 45 | 45 | – |
| 125  | ATTR | Yes | LV septum (mm) | 14‡ | 14‡ | 14 | 14 | 14 | 15 | 17 | 15 | 15 |
| LV posterior wall thickness (mm) | 13‡ | 13‡ | 14 | 14 | 14 | 15 | 15 | 15 | 15 |
| E:E’ | 6.6‡ | 6.6‡ | 9 | 8 | 10.871 | 11 | 13.1 | 8.61 | 11 |
| LVEF (%) | 60‡ | 60‡ | 55 | 60 | 55 | 49 | 49 | 60 | 60 |
| Non-therapeutic dose in FIH study |
| 001  | AA | No | LV septum (mm) | 11‡ | 11‡ | – | – | – | – | – | – | – |
| LV posterior wall thickness (mm) | 11‡ | 11‡ | – | – | – | – | – | – | – |
| E:E’ | 9.5‡ | 9.5‡ | – | – | – | – | – | – | – |
| LVEF (%) | 65‡ | 65‡ | – | – | – | – | – | – | – |

Follow-up visits are presented in chronological order per parameter as given in the database. These visits will therefore occur at different times relative to baseline for each patient and parameter. Therefore, it is not possible to directly compare values at a particular visit between patients or between parameters within a patient.

\*The latest value in the database pre-baseline. The baseline date was defined as the date of first pharmacologically active administration of dezamizumab (i.e. 200 mg in the session) in the FIH study. For patients who only received a non-pharmacologically active dose (i.e. <200 mg in the session), their baseline date was defined as the date of first administration of a non-pharmacologically active dose of dezamizumab.

†Experienced clonal relapse during parent study and/or follow-up (see manuscript **Table 3** footnotes for details).

‡1st value post diagnosis and value at baseline were measured at the same study visit.

AA, serum amyloid A; AFib, fibrinogen A alpha-chain; AL, immunoglobulin light chain; ApoA1, apolipoprotein A-I; ATTR, transthyretin; E:E’, early mitral inflow velocity and mitral annular early diastolic ratio; FIH, first-in-human; LV, left ventricle; LVEF, left ventricular ejection fraction.